iCare
iCare (Icare Finland Oy) is a Finnish ophthalmic medical device subsidiary of Revenio Group that develops the FDA-cleared DRSplus fundus imaging system and AI-enabled retinal screening tools for hospitals, ophthalmology practices, and primary care providers.
- Company typePrivate
- Founded2003
- HeadquartersVantaa, Finland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What iCare does
iCare (legal entity: Icare Finland Oy) is a Finnish ophthalmic medical device company and wholly-owned subsidiary of Revenio Group Corporation, headquartered in Vantaa, Finland. The company develops and manufactures hardware and software solutions for retinal screening, diagnostics, and monitoring, with its core product being the DRSplus Fundus Imaging System—an FDA 510(k) cleared device commercially available in the United States for diabetic retinopathy screening and cardiovascular disease risk assessment. iCare generates revenue primarily through hardware sales of medical diagnostic devices to healthcare providers and eyecare professionals, supplemented by AI software integration potential via licensing and royalty arrangements. The company serves two principal customer segments: hospitals, ophthalmology practices, and primary care settings that need retinal screening capabilities, and eyecare professionals requiring advanced diagnostic and imaging solutions. iCare sells through direct enterprise field sales channels globally, targeting hospitals, ophthalmology practices, and primary care settings with positioning around the lack of ophthalmologist access in primary care and the efficiency benefits of AI-enabled screening. Following the August 2024 acquisition of Dutch AI specialist Thirona Retina BV and the June 2026 integration of Visionix's ophthalmic portfolio, iCare now offers a comprehensive suite spanning diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals worldwide.
iCare firmographics
Firmographics- Name
- iCare
- Legal name
- Icare Finland Oy
- Website
- https://icare-world.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- iCare (Icare Finland Oy) is a Finnish ophthalmic medical device subsidiary of Revenio Group that develops the FDA-cleared DRSplus fundus imaging system and AI-enabled retinal screening tools for hospitals, ophthalmology practices, and primary care providers.
- Ownership category
- akta.pro rank
iCare industry classification
Industry- Product category
- Ophthalmic Diagnostic Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
Keywords
Where iCare is headquartered
LocationHeadquarters
- HQ city
- Vantaa
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
iCare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Medical Device Sales: iCare generates revenue through sale of medical diagnostic devices including fundus imaging systems and related ophthalmic equipment to healthcare providers and eyecare professionals
- AI Software Integration: Revenue potential from AI-powered diagnostic software integrated with medical devices for retinal screening and cardiovascular risk assessment
Go-to-market motion2 records
Distribution channels2 records
Marketing channels1 record
iCare product offering
Product offeringCore offering
iCare develops and manufactures ophthalmic medical devices, most notably the DRSplus Fundus Imaging System, used for retinal screening, diabetic retinopathy detection, and cardiovascular disease risk assessment. The portfolio has expanded through the Visionix merger to include diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals and primary care providers.
Product overview
iCare is a subsidiary of Revenio Group Corporation that develops and manufactures ophthalmic medical devices and AI-enabled diagnostic solutions. The company's product portfolio centers on the DRSplus Fundus Imaging System, an FDA 510(k) cleared retinal screening device. Following the acquisition of Thirona Retina (AI for retinal image analysis) and the merger with Visionix's ophthalmic device and imaging portfolios, iCare now offers a comprehensive suite including diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals. The company also partners with Mediwhale to integrate its fundus imaging with AI-powered cardiovascular disease risk assessment software.
Differentiator
Problem solved
Functional benefit
Products and services
- DRSplus Fundus Imaging System An FDA 510(k)-cleared TrueColor confocal fundus camera system used by healthcare providers, primary care settings, and ophthalmology practices for retinal screening, diabetic retinopathy detection, and cardiovascular disease risk assessment.
- Visionix Ophthalmic Portfolio A multi-modality ophthalmic product line resulting from the Visionix merger, encompassing diagnostic imaging, optical coherence tomography (OCT), refraction technology, and AI-enabled workflow solutions for eyecare professionals.
Quantifiable outcome
- iCare's DRSplus device is FDA 510(k) cleared and commercially available in the United States
- +1 more outcomes
Companies that use iCare
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
iCare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature3 records
iCare partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- VisionixflagshipRevenio Group Corporation officially completed the integration of Visionix's ophthalmic medical device and imaging portfolios with iCare, after announcing the acquisition over a month ago. Revenio purchased Visionix's entire capital share from its French parent company, LT International SAS, creating a combined entity offering diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals.
- Mediwhale Inc.coreiCare, a subsidiary of Revenio Group, and South Korea-based Mediwhale Inc. agreed to explore a strategic collaboration integrating iCare's DRSplus fundus imaging system with Mediwhale's Dr. Noon CVD AI software to create a retinal imaging-based platform for cardiovascular disease risk assessment. iCare's device is already FDA 510(k) cleared and commercially available in the United States, while Mediwhale is pursuing FDA De Novo authorization with an estimated H1 2026 timeframe. The partnership aims to establish retinal screening as a tool for systemic health management beyond ophthalmology.
- Thirona Retina B.V.coreIcare Finland Oy acquired Thirona Retina B.V., a Dutch company specializing in artificial intelligence for retinal image analysis. This acquisition enhances iCare's AI capabilities for retinal screening technology.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
iCare competitors and assessment
Company assessmentDirect peers
- Eyenuk: Eyenuk is a U.S.-based AI diagnostics company specializing in autonomous diabetic retinopathy screening via fundus imaging — directly competing with iCare's DRSplus + Thirona Retina AI offering in primary care screening workflows.
- Digital Diagnostics: Digital Diagnostics develops IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy — a direct competitor to iCare's AI-enabled DR screening positioning in U.S. primary care.
- AEYE Health: AEYE Health is an AI retinal screening company focused on autonomous DR detection from fundus images — directly comparable to iCare's Thirona Retina-powered AI screening capability.
- Optomed: Optomed is a Finnish-listed handheld fundus camera and AI screening company — directly competing with iCare's DRSplus in primary care DR screening, and a Nordic peer with similar OEM/screening positioning.
- IRIS (Intelligent Retinal Imaging Systems): IRIS provides AI-enabled retinal screening services in U.S. primary care settings — directly competing with iCare's primary-care DR screening go-to-market motion.
Broad incumbents
- Topcon Healthcare: Topcon is a large Japanese ophthalmic device incumbent offering fundus cameras, OCT, and screening software — competing with the iCare/Visionix combined portfolio across eyecare professionals globally.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic device leader (OCT, fundus, surgical) — a broad incumbent competing with iCare's expanded portfolio post-Visionix integration in eyecare practices and hospitals.
- Heidelberg Engineering: Heidelberg Engineering specializes in retinal imaging (SPECTRALIS OCT, fundus) — a premium-incumbent peer competing with iCare's DRSplus and integrated imaging portfolio.
- Nidek: Nidek is a Japanese ophthalmic device manufacturer with fundus cameras, OCT, and refraction equipment — overlapping with the iCare/Visionix merged portfolio across eyecare professionals.
Emerging players
- Mediwhale: Mediwhale is a South Korean AI health company developing Dr. Noon CVD (retinal imaging-based cardiovascular risk assessment) — both a partner and adjacent competitor in retinal AI, pursuing FDA De Novo authorization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
iCare social profiles
Digital presenceiCare compliance and trust
Trust signalCompliance1 record
iCare financial estimates
Financial estimateRevenue estimate
Valuation estimate
iCare leadership team
Management profileNumber of profiles
Profiles2 records
iCare subsidiaries and ownership
Company hierarchySubsidiaries2 records
iCare funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iCare M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iCare
What does iCare do?
iCare develops and manufactures ophthalmic medical devices, most notably the DRSplus Fundus Imaging System, used for retinal screening, diabetic retinopathy detection, and cardiovascular disease risk assessment. The portfolio has expanded through the Visionix merger to include diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals and primary care providers.
Is iCare a public or private company?
iCare is a private company. It is classified as corporate owned and is currently operating.
When was iCare founded?
iCare was founded in 2003. It employs 101 to 250 people.
Where is iCare based?
iCare is headquartered in Vantaa, Finland, in the Europe region.
How does iCare make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are AI Software Integration.
Who are iCare's main competitors?
Direct peers on record are Eyenuk, Digital Diagnostics, AEYE Health, Optomed and IRIS (Intelligent Retinal Imaging Systems). Broad incumbents are Topcon Healthcare, Carl Zeiss Meditec, Heidelberg Engineering and Nidek. Mediwhale is listed as an emerging player.
Does iCare have an API?
No public API is recorded for iCare.
What industry is iCare in?
iCare's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 339112 and its SIC code is 3841.